Atara Biotherapeutics (ATRA) Earnings Analysis

Atara Biotherapeutics (ATRA) next reports earnings on 2026-08-10, consensus EPS -0.315 USD. Last quarter (2026-05-14) it beat with EPS -0.29 USD vs -0.32953 USD est (+12%). It has beaten estimates in 5/7 recent quarters (71%). Trailing P/E -12.31.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ATRA next report earnings?

Next earnings date2026-08-10
Consensus EPS estimate-0.315 USD
Revenue estimate0.00B

ATRA earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-14-0.29 USD-0.32953 USD+12%Beat
2026-03-16-0.25 USD-0.09 USD-177.8%Miss
2025-11-12-0.32 USD-0.83 USD+61.4%Beat
2025-08-110.19 USD-0.32 USD+159.4%Beat
2025-05-153.5 USD-3.07 USD+214%Beat
2025-03-07-1.19 USD-3.82 USD+68.8%Beat
2024-08-12-3.1 USD-1.25 USD-148%Miss

Beat rate: 5/7 (71%) over reported quarters with consensus data.

ATRA valuation and analyst view

Trailing P/E-12.31
Trailing EPS-0.67232 USD
Price / book-3.07
Dividend yield0.00%
Market cap0.08B
Analyst consensusHold (4 buy / 7 hold / 2 sell)
Avg price target13 USD

Related research pages

Frequently asked questions

When is Atara Biotherapeutics (ATRA)'s next earnings date?

Atara Biotherapeutics is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -0.315 USD and revenue estimate of 0.00B.

Did ATRA beat earnings last quarter?

In its 2026-05-14 report, ATRA posted EPS of -0.29 USD versus a -0.32953 USD estimate — a beat of 12%.

What is ATRA's earnings track record?

Over the last 7 reported quarters with consensus data, ATRA beat estimates 5 times (71%).

What is ATRA's current P/E ratio and EPS?

ATRA trades at a trailing P/E of -12.31 on trailing EPS of -0.6723244087777857 USD.

What do analysts rate ATRA?

Analyst consensus is "Hold" across 13 ratings (0 strong buy, 4 buy, 7 hold, 2 sell, 0 strong sell). Average 12-month price target: 13 USD.